Product Name: RetSubtide
Product Number: PE-01BJC
Size:      $US
Peptide Name: RetSubtide

Product Use: For assaying the phosphotransferase activity of Proto-oncogene tyrosine-protein kinase receptor Ret (UniProt ID P07949).

Peptide Production Method: Solid-phase peptide synthesis

Peptide Sequence: KKGIEDDDYVNPGG

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys

Storage Conditions: -20°C

Peptide Recommended Enzyme: Ret

Scientific Background: Ret is a receptor protein-tyrosine in the TK group of protein kinases in the Ret family. It is highly expressed and widely distributed in most tested human tissues. Ret is activated by binding one of four structurally ligands (i.e. GDNF, neurturin, artemin and persephin). Autophosphorylation of S696, Y806, Y809, Y864, Y900, Y905, Y928, Y952, Y981 and Y1062 of Ret increases its phosphotransferase activity. Phosphorylation of Y1015 inhibits its phosphotransferase activity. Protein interactions are induced with phosphorylation of Y981 (with Src), Y1062 (with Crk, Dok6, FRS2, Gab1, IRS1, PIK3R1, RapGEF1, Shc1 & Shc3), and Y1096 (with Grb2 & PIK3R1). Phosphorylation of Y1015 inhibits kinase activity. Ret orchestrates intestine organogenesis. Germline mutations of Ret cause a dominantly inherited dysgenesis of the enteric nervous system known as Hirschsprung's disease. Ret can undergo oncogenic activation by cytogenetic rearrangement. It is constitutively activated by point mutations in hereditary medullary thyroid carcinomas (MTCs). Multiple endocrine neoplasia type 2A (MEN 2A) is associated with two mutations of Ret. It was identified as a potential low-penetrance gene for apparently sporadic pheochromocytoma. Ret has also been linked with congenital central hypoventilation syndrome, bladder carcinomas, and colorectal adenocarcinomas.